Moderna Inc at Piper Sandler Healthcare Conference Transcript
Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, firstly, thank you all for joining us.
And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and Moderna that are posted at the back of the room and also at the registration desk.
So I don't think Moderna needs much of an introduction these days. I remember when we first did the IPO, it took a little bit more, but now pretty much a household name, thanks to all of your hard work in protecting us against the COVID pandemic.
But what I really love about the story, I think it's just getting excited now, because you have a dramatically strengthened balance sheet and really a fundamentally derisked technology and are developing a pipeline of new mRNA vaccines and medicines that I think are even going to have a bigger impact.
I'm very pleased to have my good friend, Stephane Bancel. Thanks for taking the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |